

PATRICK DEVAL L
Form 4
July 10, 2018

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
PATRICK DEVAL L

2. Issuer Name and Ticker or Trading Symbol
Global Blood Therapeutics, Inc.
[GBT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2018

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BLVD, SUITE 300

(Street)

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--------|---|--|---|------------|-------|
| | | | | Code | V | Amount | | | | (A) or (D) | Price |
| Common Stock | 07/06/2018 | | M | | | 15,000 | A | \$ 28.45 | 15,000 | D | |
| Common Stock | 07/06/2018 | | M | | | 15,000 | A | \$ 20 | 30,000 | D | |
| Common Stock | 07/06/2018 | | M | | | 8,361 | A | \$ 20 | 38,361 | D | |
| Common Stock | 07/06/2018 | | M | | | 4,018 | A | \$ 3.4 | 42,379 | D | |

Edgar Filing: PATRICK DEVAL L - Form 4

| | | | | | | | |
|-----------------|------------|---|--------|---|---------------|---|---|
| Common Stock | 07/06/2018 | S | 42,379 | D | \$ 43.4008 | 0 | D |
| | | | | | <u>(1)</u> | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| Employee Stock Option (right to buy) | \$ 28.45 | 07/06/2018 | | M | 15,000 | <u>(2)</u> 06/19/2027 | Common Stock 15,000 |
| Employee Stock Option (right to buy) | \$ 20 | 07/06/2018 | | M | 15,000 | <u>(3)</u> 08/10/2025 | Common Stock 15,000 |
| Employee Stock Option (right to buy) | \$ 20 | 07/06/2018 | | M | 8,361 | <u>(4)</u> 08/20/2025 | Common Stock 8,361 |
| Employee Stock Option (right to buy) | \$ 3.4 | 07/06/2018 | | M | 4,018 | <u>(5)</u> 04/08/2025 | Common Stock 4,018 |

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Director 10% Owner Officer Other

PATRICK DEVAL L
 C/O GLOBAL BLOOD THERAPEUTICS, INC.
 171 OYSTER POINT BLVD, SUITE 300
 SOUTH SAN FRANCISCO, CA 94080

X

Signatures

/s/Lesley Ann Calhoun, as
 Attorney-in-Fact

07/10/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Represents the weighted average sale price of the shares sold ranging from \$43.35 to \$43.85 per share. The Reporting Person will
 - (1) provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
 - The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors, such that this option became fully exercisable on June 20, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.
 - (2) 2017, subject to the recipient's continued service on the Issuer's Board of Directors, such that this option became fully exercisable on June 20, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.
 - The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on
 - (3) September 11, 2015, such that this option became fully exercisable on August 11, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer.
 - The shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on August
 - (4) 23, 2015, such that this option is fully exercisable on July 23, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.
 - (5) 25% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.